Stereotaxis' Robocath system achieves 100% clinical success in 20-patient coronary intervention study
STXS•Stereotaxis said its subsidiary Robocath’s next-generation coronary intervention robot achieved clinical success in all 20 patients in a first-in-human study, with no device-related adverse events through 30-day follow-up.
1. Study results
Stereotaxis announced first-in-human study results for subsidiary Robocath’s next-generation coronary intervention robot. All 20 patients achieved clinical success, with no device-related adverse events through 30-day follow-up, including patients with complex coronary disease. The findings were presented at the Transcatheter Cardiovascular Therapeutics conference on November 1, 2026.
